LeucoPatch in the Management of Hard-to-heal Diabetic Foot Ulcers

LeucoPatch in the Management of Hard-to-heal Diabetic Foot Ulcers

Diabetic foot ulcers are the source of considerable suffering and cost and there are currently no wound care products available that have been demonstrated to improve healing, or that are cost effective. There have however been a small number of studies which have examined the use of platelets or fluid derived from platelets, either from the patient's own blood or from blood bank products. These have suggested some promise, but have suffered from technical difficulties in making a suitable wound care product or the volume of blood required to derive the product. It is thought that the reason why they may work is that growth factors released by the platelets may stimulate the wound to heal.

This study will be a formal, randomised controlled trial to assess a new device for creating a wound care product which is a plug or patch comprising fibrin, white cells and platelets derived from 18 mls of the patients own blood. The application of this fibrin/white cell/platelet patch to the patients wound on a weekly basis will be compared with usual best care in patients with hard to heal Diabetic Foot Ulcers in a secondary care setting in 25 centres in the United Kingdom, Denmark and Sweden.

Inclusion Criteria:

• People aged 18 years and over who have diabetes complicated by one or more ulcers on a foot or both feet below the level of the malleoli, excluding ulcers confined to the interdigital cleft.
• Those with more than one eligible ulcer will have one - usually the largest or more clinically significant - selected at screening as the index ulcer.
• Eligible ulcers will be hard-to-heal, meaning that the cross-sectional area will decrease by less than 50 % during a four week run-in period.
• The cross-sectional area of the index ulcer will be ≥50 and ≤1000 mm2 at the end of the 4 week run-in period.
• At randomisation, the index ulcer will be clinically non-infected according to IDSA criteria
• Either the ankle-brachial index (ABPI) in the affected limb will be between 0.50 and 1.40 or the dorsalis pedis pulse and/or tibialis posterior pulse will be palpable.
• HbA1c ≤108 mmol/mol at screening
• Participants will have the capacity to understand study procedures, and will be able to provide written informed consent.

Exclusion Criteria:

• Haemoglobin concentration <105 g/L or 6.5 mmol/L at screening.
• Presence of sickle-cell anaemia, haemophilia, thrombocytopenia (<100x109/L) or other clinically significant blood dyscrasia
• Known potential infectivity of blood products, including known HIV and hepatitis
• Dialysis or an estimated GFR (based on cystatine C or serum creatinine) <20 ml/min/1.73m2
• Increase in cross-sectional area of the index ulcer by ≥25% during the 4 week run-in period, or is either smaller than 50 mm2 or larger than 1000 mm2 at the end of that time.
• Clinical signs of infection of the index ulcer or reason to suspect that infection is present at randomisation.
• Revascularisation procedure in the affected limb planned, or undertaken within the preceding 4 weeks.
• Current treatment with cytotoxic drugs or with systemically administered glucocorticoids or other immunosuppressants.
• Treatment of foot ulcers with growth factors, stem cells or equivalent preparation within the preceding 8 weeks
• The need for continued use of negative pressure wound therapy
• Likely inability to comply with the need for weekly visits because of planned activity.
• Participation in another interventional clinical foot ulcer-healing trial within last the 4 weeks at the time of screening.
• Prior randomisation in this trial.
• Judgement by the investigator that the patient does not have the capacity to understand the study procedures or provide written informed consent.